

Shalby/SE/2026-27/17

May 27, 2026

The Listing Department
National Stock Exchange of India Ltd
Mumbai 400 051.

Scrip Code : SHALBY

Through : <https://neaps.nseindia.com/NEWLISTINGCORP/>

Corporate Service Department

BSE Limited

Mumbai 400 001.

Scrip Code: 540797

Through : <http://listing.bseindia.com>

Sub: Investor Presentation for the quarter and year ended 31st March 2026

Dear Sir / Madam,

We are submitting herewith Investor Presentation on financial & operational performance of the Company for the Quarter and year ended March 31, 2026, which will be discussed at the Investor Conference call scheduled on i.e. on May 29, 2026 at 5:00 p.m IST.

The said Investor Presentation is being uploaded on website of our Company at <https://www.shalby.org/investors/> → Investors Presentation.

You are requested to take the same on your record.

Thanking you,

Yours sincerely

For **Shalby Limited**

Tushar Shah

Vice President & Company Secretary

Mem. No: FCS-7216

Encl.: as above



SHALBY LIMITED

•Passion•Compassion•Innovation•

Investor Presentation

Q4 & FY2026



This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful.

This presentation has been prepared by **Shalby Limited (the "Company")**. These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan or any other jurisdiction. Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of any securities of the Company is being made in the United States.

The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction.

No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith. The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially. Financial information contained in this presentation has been derived from the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point.

This presentation contains certain "forward looking statements". Forward-looking statements are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Although the Company believes that such forward-looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained in this presentation will actually be achieved. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose. No responsibility or liability whatsoever is undertaken for the contents hereof.

This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm.

AGENDA

01

SHALBY CONSOLIDATED QUARTERLY & ANNUAL PERFORMANCE

02

SHALBY STANDALONE QUARTERLY & ANNUAL PERFORMANCE

03

SHALBY INTERNATIONAL QUARTERLY & ANNUAL PERFORMANCE

04

SHALBY MEDTECH QUARTERLY & ANNUAL PERFORMANCE

05

ABOUT SHALBY LIMITED

Consolidated Financial Highlights

Consolidated Total Revenue at ₹ 2,955 mn in Q4 FY26 vs ₹ 2,702 mn in Q4 FY25

Consolidated EBITDA at ₹ 374 mn in Q4 FY26 vs ₹ 262 mn in Q4 FY25

Consolidated PBT at ₹ 96 mn in Q4 FY26 vs ₹ (7) mn in Q4 FY25

Consolidated Net debt stood at ₹ 4,462 mn as on March'26

Consolidated Annualized ROCE stood at 7.3%

Standalone Financial Highlights

Standalone Total Revenue at ₹ 2,304 mn in Q4 FY26 vs ₹ 2,142 mn in Q4 FY25

Standalone EBITDA at ₹ 371 mn in Q4 FY26 vs ₹ 380 mn in Q4 FY25

Standalone PBT at ₹ 235 mn in Q4 FY26 vs ₹ 257 mn in Q4 FY25


Standalone Net debt stood at ₹ 438 mn as on March'26

Standalone Annualized ROCE stood at 10.8%


Consolidated Performance Highlights – Q4 FY26

Financial Performance (in INR Mn)


Total Revenue




EBITDA¹ & Margin



PBT & Margin




PAT² & Margin




1. EBITDA includes other income 2. Adoption of New Tax Regime.

Financial Performance (in INR Mn)


Total Revenue




EBITDA¹ & Margin



PBT & Margin



PAT² & Margin



1. EBITDA includes other income 2. Adoption of New Tax Regime.

Profit & Loss

Particulars (INR Mn)	Q4 FY26	Q3 FY26	Q4 FY25	Q-o-Q Growth	Y-o-Y Growth
Total Revenue	2955	2794	2702	5.8%	9.4%
EBITDA²	374	375	262	(0.1%)	43.1%
<i>EBITDA Margin %</i>	<i>12.7%</i>	<i>13.4%</i>	<i>9.7%</i>		
PBT	96	92	(7)	4.1%	1399.9%
<i>PBT Margin %</i>	<i>3.3%</i>	<i>3.3%</i>	<i>(0.3)%</i>		
PAT³	185	13	(122)	1344.0%	251.4%
<i>PAT Margins %</i>	<i>6.2%</i>	<i>0.5%</i>	<i>(4.5%)</i>		

Balance Sheet (INR Mn)

Gross Borrowings	5396
Cash & Cash Equivalents	934
Net Cash/(Debt)	(4462)
Debt/Equity	0.44x
ROCE¹	7.3%

Notes:

1. ROCE= Annualized EBIT/ Average (Equity +Debt- Cash & Cash Equivalent) 2. EBITDA includes other income. 3. Adoption of New Tax Regime.

Shalby Limited : Consolidated Revenue & EBITDA Breakup – Q4 FY26


	Revenue (%)	Revenue (in INR Mn)	EBITDA (in INR Mn)
Shalby Hospitals, Pharma & Franchise ¹	79.16%	2339.5	342.2
Shalby International (PK Healthcare, Delhi-NCR) ²	7.26%	214.7	(3.6)
Shalby MedTech (Implant Business)	13.55%	400.4	37.2
Others	0.03%	0.8	(1.5)
Shalby Limited (Consolidated)	100%	2955.4	374.3

Notes:


1. Includes Shalby Academy, Slaney and Griffin which is into pharmacy trading 2.Includes fellow subsidiaries in Delhi-NCR region.

Financial Trends – Shalby Limited (Consolidated)


Total Revenue (In INR Crs)



EBITDA (In INR Crs) & Margin (%)



ROCE (%)



SHALBY LIMITED BUSINESS VERTICALS

SHALBY
MULTI-SPECIALTY
HOSPITALS



SHALBY
MedTech




Dr Vikram I Shah,
Founder & Chairman

Dr Vikram I. Shah, the Founder of Shalby Ltd, is a world-renowned Joint Replacement Surgeon who innovated the “**Zero Technique**” that revolutionized Joint Replacement Surgery.

A visionary entrepreneur, he transformed Shalby from a 6-bedded hospital in 1994 to an integrated healthcare group with 13 hospitals network and 2200+ beds across 10 cities in India, with an implant manufacturing facility in California, USA and a distribution facility in India and South-East Asian countries.

Shalby is today the Biggest Corporate Hospital Group in Western and Central India, focusing on all major disciplines in medicine, with credentials of being the Largest Joint Replacement Centre of the World, having done over 1,75,000+ successful joint replacement surgeries till date.


Shalby Limited is listed on both the premier stock exchanges in India and has the aspiration of growing multifold while preserving the core values of “Passion, Compassion and Innovation”.




STANDALONE BUSINESS PERFORMANCE

Financial Performance (in INR Mn)


Total Revenue




EBITDA¹ & Margin



PBT & Margin




PAT² & Margin




1. EBITDA includes other income 2. Adoption of New Tax Regime.

Financial Performance (in INR Mn)


Total Revenue




EBITDA¹ & Margin



PBT & Margin



PAT² & Margin




1. EBITDA includes other income 2. Adoption of New Tax Regime.

Profit & Loss

Particulars (INR Mn)	Q4 FY26	Q3 FY26	Q4 FY25	QoQ Growth	YoY Growth
Total Revenue	2304	2210	2142	4.3%	7.6%
EBITDA²	371	354	380	4.6%	(2.4%)
<i>EBITDA Margin %</i>	16.1%	16.0%	17.7%		
PBT	235	219	257	7.3%	(8.6%)
<i>PBT Margin %</i>	10.2%	9.9%	12.0%		
PAT³	537	138	150	290.0%	259.6%
<i>PAT Margin %</i>	23.3%	6.2%	7.0%		

Total Revenue to EBITDA




Balance Sheet as on March'26 (INR Mn)

Gross Borrowings	1197.41
Cash & Cash Equivalents	759.28
Net Cash/(Debt)	(438.12)
ROCE¹ (annualized)	10.8%

Notes:

1. ROCE= Annualized EBIT/ Average (Equity +Debt- Cash & Cash Equivalent) 2. EBITDA includes other income. 3. Adoption of New Tax Regime.


Shalby International Q4'FY26 Highlights




Shalby International Performance Highlights – Q4 FY26

Financial Performance (in INR Mn)


Total Revenue




EBITDA¹



PBT



PAT




1. EBITDA includes other income


Shalby International Performance Highlights – FY26

Financial Performance (in INR Mn)


Total Revenue




EBITDA¹



PBT



PAT



1. EBITDA includes other income

Hospital Business Highlights Q4 FY26

Surgery Count and YoY Performance



Arthroplasty

2650+ ↓ 15.4%



Orthopaedic

1100+ ↔



Oncology

420+ ↓ 17.4%



General & Cosmetics

900+ ↑ 11.4%



Nephro & Urology

650+ ↑ 14.8%



Other Surgery

1,170+ ↓ 7.3%

Operational Performance³


Particulars	Q4 FY26	Q4 FY25	YoY Growth
In-Patient ¹ (Nos.)	21,551	21,202	1.6%
Out Patient (Nos.)	1,22,887	1,31,271	(6.4%)
Surgeries Count	6,909	7,405	(6.7%)
ARPOB (In Rs.)	42,689	41,585	2.7%
Operational Beds ² (Nos.)	1,365	1,415	(3.5%)
Occupied Beds	649	633	2.4%
Occupancy Rate ⁴	48%	45%	276bps
ALOS (without Daycare)	3.81	3.68	3.5%

Notes:


1. In-Patient count Includes Day care count 2. Included operational beds in (FOSO) SOCE unit 3.Q4'FY26 & Q4'FY25 numbers include PK Healthcare performance. 4. Occupancy Rate excluding PK Healthcare is 50%.

Specialty Revenue Mix

Q4 FY2025²




Q4 FY2026²




Notes:
 1. Orthopaedic includes Spine. 2. Q4'FY25 & Q4'FY26 numbers include PK Healthcare performance.

Payor Mix

Q4 FY2025¹



Q4 FY2026¹



Notes:
1. Q4'FY25 & Q4'FY26 numbers include PK Healthcare performance.

Maturity Wise Hospital Performance – Q4 FY26¹


Maturity	No. of Hospitals	Total Revenue (in INR Mn)	Operational Beds	ARPOB	EBITDA (in INR Mn)	EBITDA Margin (in%)
10+ Years	7	1482.9	808	47,258	300.6	20.3%
5-10 Years	3	747.0	427	29,629	118.5	15.9%
0-5 Years	1	215.3	130	88,592	(19.6)	(9.1%)
Corporate ^{2,3}	-	74.5	-	-	(48.6)	(65.2%)
Total	11	2519.7	1365	42,689	350.9	13.9%

Notes:


1. Q4'FY26 numbers include PK Healthcare performance 2. Corporate revenue includes MF gains & FD interest, FOSM revenue sharing (Franchise Network- Zynova and Gwalior), interest and corporate guarantee commission income from inter-company loans. 3. EBITDA loss includes Corporate employees' expense and other common administrative expenses.

Financial Trends – Standalone Business ¹


Total Revenue (In INR Cr)




EBITDA (In INR Cr) & Margin (%)



PAT (In INR Cr) & Margin (%)



ROCE (%)




Notes:


1. Above metrics are excluding of PK Healthcare & FOSM.

Operational Trends – Hospital Business ^{1,2}


Bed Capacity




Operational Beds




Occupied Beds




Total Surgeries Count



ARPOB (in INR)



ALOS



Notes:
 1. Above metrics are inclusive of PK Healthcare & FOSO. 2. Bed Capacity includes PK Healthcare, FOSO & Shalby Zynova.

Key Focus Areas For Future In Hospital business

Global Leader in Joint Replacement with diversification in other specialties

- Continue to maintain global leadership in joint replacements
- Ongoing diversification with Cardiac Science, Oncology, Neuro-science, Critical Care, General Medicine and Transplants

Prudent Capital Allocation

- Sustainable Capex business model whereby becoming a preferred O&M partner on revenue sharing mode
- Focus to doubling ROCE in coming year due to operational leverage

Growth in Occupancy Rate

- Additional 40% of the total bed capacity is available to support organic growth trajectory with limited capex

24x7 Homecare Services

- Provide Quality Services Through High-end digital systems
- Growing no of services and markets outside home locations


Leveraging Technology

- Adoption and leveraging technology to provide better medical outcomes, patient reach and satisfaction

Expansion Plan

- Mumbai hospitals within development budget and provide access to important local markets






IMPLANT BUSINESS



Shalby's Company Structure of Implant Business




* Shalby MedTech Limited (SMTL) formerly known as Mars Medical Devices Limited. (MMDL)

Shalby MedTech Performance Highlights: Q4 FY26


Financial Performance (in INR Mn)

Total Revenue



	SMTL	SAT, Inc.	SGTPL	SMTL Consol.
■ Q4 FY25	117.43	276.77	26.47	275.92
■ Q3 FY26	189.58	264.60	17.23	303.84
■ Q4 FY26	280.89	326.03	12.88	400.36
QoQ Growth %	48%	23%	-25%	32%
YoY Growth %	139%	18%	-51%	45%

Total EBITDA




	SMTL	SAT, Inc.	SGTPL	SMTL Consol.
■ Q4 FY25	(26.05)	(71.50)	4.19	(93.35)
■ Q3 FY26	5.50	15.97	1.87	0.74
■ Q4 FY26	10.12	146.00	(5.94)	37.16
QoQ Growth %	84%	814%	-418%	4948%
YoY Growth %	139%	304%	-242%	140%

Shalby MedTech Performance Highlights: FY26




Financial Performance (in INR Mn)

Total Revenue



	SMTL	SAT, Inc.	SGTPL	SMTL Consol.
■ FY 24	156.74	786.02	14.49	584.41
■ FY 25	352.04	1,081.82	63.72	922.86
■ FY 26	813.11	1,168.23	63.05	1,349.72
YoY Growth %	131%	8%	-1%	46%

Total EBITDA




	SMTL	SAT, Inc.	SGTPL	SMTL Consol.
■ FY 24	(17.25)	1.18	(8.00)	(48.52)
■ FY 25	(116.76)	(77.92)	9.91	(191.65)
■ FY 26	(7.10)	210.15	(0.99)	67.04
YoY Growth %	94%	370%	-110%	135%

Shalby MedTech Consolidated Inventory



SMT Consolidated Inventory
(in INR mn)



CORE STRATEGIC PILLARS



USA




SINGAPORE




INDIA

- Recruitment, retention & training of sales and corporate teams.
- Strong employee engagement, involvement and regular communication.
- Clear career development pathway.
- Rewards and recognition.
- Annual goals and performance planning.



- Continual training of employees, HCPs and Channel Partners.
- Solid Partner Relationship.
- Achieve industry-best talent.
- Implement robust succession planning process.
- Scale leadership development programs.

Implant Business Footprint Global



Existing Markets

- North America
- Japan
- India
- Indonesia

Approval Received

- Malaysia
- Argentina

Regulatory Approvals

- South Korea
- Vietnam
- Iran

Upcoming Markets

- Nepal
- Iraq
- Ethiopia
- Paraguay
- Sri Lanka
- Russia


Implant Business Footprint Across India

Existing Markets

- Andhra Pradesh
- Chhattisgarh
- Gujarat
- Haryana
- Karnataka
- Madhya Pradesh
- Maharashtra
- Punjab
- Rajasthan
- Tamil Nadu
- Telangana
- West Bengal

Upcoming Markets

- Assam
- Odisha
- Uttar Pradesh
- Uttarakhand



Marketing Engagements

Q4 2025-26 Highlights

23–25 Jan 2026
INDORE

- **INDOCON 2026,**
- Indore Cadaver workshop, DAA discussions, and REVSET innovation showcase.

25 Jan 2026
Ahmedabad

- **Ahmedabad Orthopedic Conference**
- Academic engagement focused on TUKSplasty and orthopedic advancements.


7–8 Feb 2026
New Delhi

- **AIIMS DAA Conference, New Delhi**
- BioSkills Lab sessions and scientific exchange on hip arthroplasty.

March 2026
Coimbatore

- **HIPNEXUS 360 x KS Ortho, Coimbatore**
- Classroom series highlighting hip arthroplasty techniques and clinical outcomes.





ABOUT SHALBY LIMITED

Shalby At A Glance

Presence



13
Hospitals¹



OPD clinics


60
Domestic

23
International²



Orthopedic Implant
Manufacturing in USA

Strength



2,200+
Bed Capacity



4,500+
Total Employees³



1,150+
Doctors⁴ Team




32
Years of Legacy

Clinical Excellence



30+
Specialties



~3.5 million+
Patients Served⁵



175,000+
Joint Replacements



#1
Global Ranking in
Arthroplasty

1. 11 Multispecialty and 2 Single Speciality, 2. East African Countries, Iraq, CIS, Dubai, Oman, Bangladesh and Nepal. 3. Including Doctors, 4. Including visiting consultants, 5. Since Inception

Integrity

Highest standards of transparency, accountability, and corporate governance

Team-Work

A patient-centric focused team with a great blend of experience, diversity, fresh thinking, with proven excellence in service

Learning

Laser sharp focus on upgrading the skills of our team and building people capability ensuring high levels of patient care

Excellence


Proven leadership in healthcare, setting up Centre of Excellence to capture massive opportunities

Empathy

Creating an equitable healthcare system keeping interests of patients and families at the focus



Our Journey & Expansion Plan




Multispecialty Hospital Units


SG Shalby




Vapi Shalby




Indore Shalby



Jaipur Shalby




Krishna Shalby



Mohali Shalby




Naroda Shalby



Jabalpur Shalby



Surat Shalby




Shalby International



BIGGEST HEALTHCARE CORPORATE GROUP IN WESTERN AND CENTRAL INDIA

Domestic Presence


- PUNJAB**
 - Mohali – 145 beds
- DELHI**
 - Gurugram – 130 beds
- RAJASTHAN**
 - Jaipur – 237 beds
- GUJARAT**
 - Ahmedabad
 - SG – 201 beds
 - Krishna – 220 beds
 - Naroda – 267 beds
 - Vijay – 27 beds
 - Vapi – 146 beds
 - Surat – 243 beds
- MADHYA PRADESH**
 - Indore – 243 beds
 - Jabalpur – 233 beds
- MAHARASHTRA**
 - Ghatkopar (Zynova) – 100 beds




Madhya Pradesh
Gwalior – 50 beds

● OPDs ◻ Owned ◻ Franchise

International OPDs



Shalby Limited Shareholding Pattern (as on 31st March'26)





From Innovation to Impact

Shalby Hospitals, Ahmedabad | 2025–26



Elekta Infinity Launched at Krishna Shalby



First Robotic Soft Tissue Surgery at SG Unit



India's First QAI-Accredited Transport at SG Unit



Leading the Future of Healthcare

SHALBY GROUP OF HOSPITALS

DELHI | MUMBAI | AHMEDABAD | INDORE | JAIPUR | JABALPUR | SURAT | MOHALI | VAPI | GWALIOR

www.shalby.org



Recognised for Excellence



Sandesh Healthcare Excellence Awards



Hurun India Healthcare Excellence



TOI Oncology Excellence Award



Best Medical Tourism Centre, Gujarat



ET Health And Tech Awards

SHALBY GROUP OF HOSPITALS

DELHI | MUMBAI | AHMEDABAD | INDORE | JAIPUR | JABALPUR | SURAT | MOHALI | VAPI | GWALIOR

www.shalby.org



SCRI

Shalby Cancer & Research Institute

SHALBY
MULTI-SPECIALTY
HOSPITALS

LAUNCH OF SCRI, SURAT

शेल्बी अस्पताल में ऑन्कोलॉजी विभाग का हुआ उद्घाटन, बाइक रैली निकाली



शेल्बी मल्टी-स्पेशियलिटी अस्पताल में महिला स्वास्थ्य व कैंसर के प्रति जागरूकता के लिए बाइक रैली निकाली गई। वहीं मनपा की स्टैंडिंग कमेटी चेयरमैन राजन पटेल, यूथ फॉर गुजरात अध्यक्ष जिग्नेश पाटिल व चैंबर अध्यक्ष निखिल मद्रासी ने ऑन्कोलॉजी विभाग व आधुनिक रेडियोथेरापी सुविधाओं का उद्घाटन किया।

MEDIA

COVERAGES

क्या आप नी रिप्लेसमेंट सर्जरी के बारे में सोच रहे हैं?

SHALBY
MULTI-SPECIALTY
HOSPITALS

SHALBY
MULTI-SPECIALTY
HOSPITALS

क्या आप नी रिप्लेसमेंट सर्जरी के बारे में सोच रहे हैं?

रोबोटिक नी रिसफॉर्मिंग सर्जरी - डॉ. प्रदीप अग्रवाल के साथ नी पेशेंट्स के लिए नई उम्मीद

रोबोटिक नी रिसफॉर्मिंग सर्जरी आज के समय की सबसे एडवांस्ड तकनीकों में से एक है। यह सर्जरी Cuvis ज्वाइंट ऑटो-नोमोयस रोबोटिक सिस्टम की मदद से की जाती है, जिससे नी रिप्लेसमेंट सर्जरी पहले से कहीं ज्यादा अक्यूरेट और सेफ हो गई है और रिकवरी भी जल्दी होती है। हाल ही में 58 साल की एक महिला (नाम बदला हुआ - मिसेज नीना) इसका सफल उदाहरण हैं। वे पिछले 12 साल से सेवरर नी पेन से परेशान थीं। उन्होंने बाइलेटरल नी रिप्लेसमेंट सर्जरी इस रोबोटिक टैकनॉलोजी से करवाई। सर्जरी के बाद वे उसी दिन चलने लगीं, उन्हें बहुत कम पोस्ट-ऑप्रेटिव पेन हुआ और उनकी रिहैबिलीटेशन भी जल्दी शुरू हो गई। यह सर्जरी डॉ. प्रदीप अग्रवाल और उनकी एक्सपर्ट टीम ने की। उनकी टीम में डॉ. अक्षय श्रीवास्तव (फैलॉट ऑर्थोपेडिक्स, एमबीबीएस एआईआईएमएस, एमएस पीजीआईएमईआई, डीएनबी एनबीई दिल्ली) भी शामिल हैं, जो एडवांस्ड ऑर्थोपेडिक ट्रीटमेंट्स के विशेषज्ञ हैं।

रोबोटिक नी रिप्लेसमेंट सर्जरी के खास फायदे

- सब-मिलीमीटर एक्यूरेसी - इन्फॉर्म की साइजिंग और अलाइनमेंट बहुत सटीक होती है।

- **पर्सनलाइस्ड 3डी सर्जिकल प्लानिंग** - हर पेशेंट की नी के हिसाब से सर्जरी की प्लानिंग होती है।
- **प्रिमियम लॉन्ग लास्टिंग इंप्लांट्स** - ड्यूरैबल अमेरिकन इंप्लांट्स लगाए जाते हैं।
- **नेचुरल नी फीलिंग** - चलने-फिरने में ज्यादा नेचुरल मूवमेंट महसूस होता है।
- **मिनिमल बोन लॉस** - हड्डी कम कटती है, इसलिए रिकवरी जल्दी होती है और कई केसिस में पेशेंट्स सेम-डे वॉक कर सकता है।
- **हायली कॉन्सिस्टेंट सर्जरी** - रोबोटिक सिस्टम से ह्यूमन एरर कम हो जाता है।

डॉ. प्रदीप अग्रवाल - ज्वाइंट रिप्लेसमेंट सर्जरी का भरोसेमंद नाम
डॉ. प्रदीप अग्रवाल शैलबी हॉस्पिटल मोहाली में चेयरमैंट & चीफ कंसलटेंट - ऑर्थोपेडिक्स & ज्वाइंट रिप्लेसमेंट सर्जरी के पद पर कार्यरत हैं। उन्हें ऑर्थोपेडिक्स और ज्वाइंट रिप्लेसमेंट सर्जरी के क्षेत्र में 41 से अधिक वर्षों का अनुभव है और वे अब तक 50,000 से ज्यादा सर्जरीज सफलतापूर्वक कर चुके हैं। वे एम.एस. (ऑर्थो) के गोल्ड मेडलिस्ट हैं और रोबोटिक नी सर्जन के रूप में अपनी विशेषज्ञता के लिए जाने जाते हैं। अपने उत्कृष्ट कार्य



Award by Governor Punjab and Administrator UT Sh Gulab Chand Kataria Ji

के लिए उन्हें कई अवार्ड्स भी मिल चुके हैं। इसके अलावा उन्हें हिमाचल प्रदेश के गवर्नर, पंजाब गवर्नर और पंजाब स्वास्थ्य मंत्री द्वारा भी उनके उत्कृष्ट योगदान और एक्सीलेंस के लिए सम्मानित किया जा चुका है।

ROBOTIC KNEE RESURFACING SURGERY

ensures precision, speedy recovery & smoother movement

STEM CELL THERAPY CIPLOSTEM is available for early painful osteoarthritis of knees



CUVIS Joint Robot

American Gold Knee Implants, Duranion, lasting 40 years are being used

DR. PRADEEP AGGARWAL
Chairman cum Chief Consultant

Robotic Joint Replacement Surgery,
Shalby Multispecialty Hospital, Phase IX, Sec. 63, Mohali. 98883-98706

MOHALI



Dr. Vikram Shah
Chairman and
Managing Director

Dr. Vikram Shah, serving as Director of the Department of Knee Replacement at Shalby Hospitals since 1993 has nearly three decades of vast professional healthcare experience across the UK, USA and India. In recognition of his outstanding contribution in the field of orthopedics for completion of 1,75,000 joint replacement surgeries, he was conferred with the 'Times Man of the Year' Award by Times of India Group in 2018.



Dr. Ashok Bhatia
Independent
Director

Mr. Ashok Bhatia is an experienced Pharmaceutical executive with over 48 years of leadership spanning sales, marketing, business development, M&A, and talent management. He dedicated 37 years to Zydus Lifesciences, where he rose to the position of President – Emerging Markets, overseeing operations across 12 markets and managing a team of over 800 professionals. He holds a Doctorate in Business Administration (DBA), an MBA, and a B.Sc., and is a guest faculty at IIM Ahmedabad and IIM Rohtak, specialising in International Marketing and Talent Management. His article 'Gender and Workplace' has been published in VIKALPA, the journal of IIM Ahmedabad.



Mr. Shyamal Joshi
Independent
Director

Associated with Shalby Hospitals since 2010, Mr. Joshi holds a bachelor's degree in commerce from Gujarat University and is a member of the ICAI. He has huge working experience that spans corporate strategy, fund raising, acquisition, merger, taxation and accounting among others. Currently, he holds directorship of various other Companies.



Mr. Tej Malhotra
Independent
Director

Mr. Malhotra comes with over four decades of experience across various industries in India and internationally. Earlier, he was associated with GHCL as Senior Executive Director, Idea Soda Ash and Calcium Chloride Company of Saudi Arabia as Technical Director and as Executive Engineer (Mechanical) at Hindustan Copper. He has been awarded the 'Bhartiya Udyog Ratan' award by the Indian Economic Development and Research Association, the 'Bhartiya Gaurav' award by the World Economic Progress Society and 'Darbari Seth Award 2009' by the Alkali Manufacturers of India for best managed soda-ash plant.



Dr. Umesh Menon
Independent
Director

Dr. Menon has deep expertise in finance and cost accounting. He also holds MBA with specialization in Finance, and a fellow member of Institute of Cost Accountants of India. He has been conferred with the Doctorate (PhD) in Management. Currently, he also serves on the board of directors of various other companies. He is also an international expert and trainer for the United Nations Industrial Development Organization.



Ms. Sujana Shah
Independent
Director

Mrs. Sujana Shah, a practicing Chartered Accountant has vast experience of nearly two decades across the domain of finance, accounts, audit, direct and indirect taxes, banking and treasury. Currently, she serves as a partner of V. R. Shah & Associates, Chartered Accountants. She has also audited many reputed public banks in India as Statutory and Internal Auditor.

Thank You

For further information, please contact:

Jigar Todi
Investors Relation & Corporate Strategist

+91 9512049871
ircs3.corp@shalby.org

SHALBY LIMITED | Regd Off: Opp. Karnavati Club, S.G. Road, Ahmedabad – 380015, Gujarat, India. Phone: 079 4020 3000 Fax: +91 79 4020 3109 |

Website: www.shalby.org | CIN: L85110GJ2004PLC044667